Research Article
Anti-VEGF Treatment of Diabetic Macular Edema: Two-Year Visual Outcomes in Routine Clinical Practice
Table 2
The proportions of eyes gaining or losing ≥10 letters and ≥15 letters.
| | Number of eyes (percentage) | | VA gain ≥10 letters | VA gain ≥15 letters | VA loss ≥10 letters | VA loss ≥15 letters | | 1 year | 2 years | value | 1 year | 2 years | value | 1 year | 2 years | value | 1 year | 2 years | value |
| | All eyes (n = 123) | 29 (23.6%) | 36 (29.3%) | 0.21 | 20 (16.3%) | 25 (20.3%) | 0.18 | 23 (18.7%) | 20 (16.3%) | 0.81 | 10 (8.1%) | 12 (9.7%) | 0.51 | | Baseline VA <70 letters (n = 77) | 28 (36.4%) | 31 (40.3%) | 0.77 | 20 (25.9%) | 25 (32.5%) | 0.18 | 14 (18.2%) | 10 (12.9%) | 0.51 | 6 (7.8%) | 7 (9.1%) | 0.62 | | Baseline VA ≥70 letters (n = 46) | 1 (2.2%) | 5 (10.9%) | 0.12 | 0 | 0 | | 9 (19.5%) | 10 (21.7%) | 1.0 | 4 (8.7%) | 5 (10.9%) | 1.0 |
|
|
Legend: VA = visual acuity.
|
